本报讯 记者郑爽报道 冬季气温骤降，寒冷天气易刺激血管收缩、血压波动，成为卒中发病的重要诱 因，让血管健康面临严峻考验。了解卒中的可控风险，并用科学方法构筑健康屏障，能有效降低发病概 率，守护身心安康。 而吸烟、酗酒、不健康饮食、缺乏运动等不良生活方式，就像潜伏的"刺客"，烟草中的有害物质会直接 损伤血管，过量饮酒会升高血压、加重心脏负担，高盐高脂高糖饮食与久坐不动则会诱发"三高"和肥 胖，此外，肥胖、过大压力、睡眠呼吸暂停综合征等也会增加卒中发病风险。 预防卒中，首先要管好血压这个"压力泵"。35岁以上人群应每年至少测量一次血压，高血压患者需遵医 嘱长期规律服药。日常饮食要严格控盐，每日摄入量控制在6克以下，多吃富含钾的蔬菜水果。同时要 关注心脏健康，定期参与体检，若发现房颤等心脏问题，需在医生指导下进行抗凝等规范治疗，从源头 预防血栓形成。在血糖血脂管理方面，定期检测是基础，糖尿病患者可通过饮食控制、适度运动和药物 治疗将血糖维持在理想范围，高血脂人群则要减少饱和脂肪与反式脂肪摄入，必要时服用他汀类药物稳 定斑块、降低血脂。 健康的生活习惯是预防卒中的"良方"。饮食上多吃蔬菜、水果、全谷物、鱼类和豆类，减 ...

Core Viewpoint - Stroke, commonly known as "cerebral infarction," is a significant health issue with high incidence, mortality, disability, and recurrence rates. It is not exclusive to the elderly, and prevention should target all age groups [1][2]. Group 1: Stroke Awareness and Prevention - Stroke is increasingly affecting younger individuals due to factors such as undiagnosed hypertension and diabetes, poor lifestyle choices like late nights, lack of exercise, and alcohol consumption [1]. - Prevention of stroke should begin in childhood, as childhood obesity significantly increases the risk of hypertension in adulthood. Parents are encouraged to manage their children's weight through diet and exercise [2]. - Middle-aged and elderly populations require focused prevention strategies, including detailed health management and regular screenings for vascular issues [2]. Group 2: Early Detection and Response - Most strokes are preventable and treatable if risk factors are identified early. The "120 mnemonic" can help recognize stroke symptoms: facial asymmetry, weakness or numbness in limbs, and language difficulties [2].

Core Viewpoint - InspireMD is accelerating its commercialization strategy in the competitive carotid intervention market following the FDA pre-market approval of its core product, CGuard® Prime carotid stent system, and a successful financing round of approximately $58 million [2][12]. Financing and Strategic Moves - InspireMD completed a financing transaction totaling approximately $58 million, which includes $40.1 million from PIPE financing led by OrbiMed and Marshall Wace, and an additional $17.9 million from warrant exercises at a price of $2.42 per share [3][12]. - The financing will be utilized for sales and marketing, R&D investments, working capital, and other operational needs to establish a comprehensive launch platform in the U.S. market [3][12]. - The appointment of Raymond W. Cohen to the board is a strategic move to enhance the company's governance and leverage his extensive experience in the medical technology sector [5][12]. Product Overview - CGuard Prime is a next-generation carotid stent system that integrates structural innovation and clinical safety, featuring proprietary MicroNet® technology designed to prevent embolic events during procedures [6][11]. - The stent's design includes an outer MicroNet® layer for continuous embolic protection and an inner SmartFit™ nickel-titanium stent that simplifies surgical operations [7][11]. Clinical Data and Market Entry - CGuard Prime demonstrated excellent safety and efficacy in the C-GUARDIANS trial, with a 30-day major adverse event rate of only 0.95% and a one-year rate of 1.93%, the lowest reported in public carotid stent studies [11][12]. - The FDA granted PMA approval for CGuard Prime in June 2025, and the company is preparing for a commercial launch in the U.S. market, supported by a national coverage decision (NCD) from CMS [12][13]. Strategic Expansion - InspireMD is exploring the adaptability of CGuard Prime for TCAR (transcarotid artery revascularization) procedures and plans to expand its product portfolio to include next-generation stent systems and integrated brain protection solutions [13][14]. - The company aims to transition from a stent manufacturer to a creator of a new paradigm in stroke intervention, leveraging clinical data and capital to drive market access and accelerate commercialization [14].